CN116144687B - Acid protease AGP and its preparation method and application - Google Patents
Acid protease AGP and its preparation method and application Download PDFInfo
- Publication number
- CN116144687B CN116144687B CN202310040621.1A CN202310040621A CN116144687B CN 116144687 B CN116144687 B CN 116144687B CN 202310040621 A CN202310040621 A CN 202310040621A CN 116144687 B CN116144687 B CN 116144687B
- Authority
- CN
- China
- Prior art keywords
- agp
- acid protease
- pepsin
- protein
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091005508 Acid proteases Proteins 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- BPHPUYQFMNQIOC-MBOVONDJSA-N (2r,3r,4s,5r)-2-(hydroxymethyl)-6-propan-2-ylsulfanyloxane-3,4,5-triol Chemical compound CC(C)SC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-MBOVONDJSA-N 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims abstract description 8
- 239000013604 expression vector Substances 0.000 claims abstract description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 10
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 abstract description 29
- 102000057297 Pepsin A Human genes 0.000 abstract description 29
- 229940111202 pepsin Drugs 0.000 abstract description 29
- 235000018102 proteins Nutrition 0.000 abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 21
- 230000002378 acidificating effect Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 102000035195 Peptidases Human genes 0.000 abstract description 12
- 108091005804 Peptidases Proteins 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 12
- 230000029087 digestion Effects 0.000 abstract description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 7
- 239000003638 chemical reducing agent Substances 0.000 abstract description 7
- 239000003398 denaturant Substances 0.000 abstract description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract description 6
- 230000000295 complement effect Effects 0.000 abstract description 6
- 235000003704 aspartic acid Nutrition 0.000 abstract description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000004472 Lysine Substances 0.000 abstract description 2
- 235000013922 glutamic acid Nutrition 0.000 abstract description 2
- 239000004220 glutamic acid Substances 0.000 abstract description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract description 2
- 108090000432 Aspergillopepsin II Proteins 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 239000004365 Protease Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001149666 Aspergillus niger var. macrosporus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003617 indole-3-acetic acid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- YYQRGCZGSFRBAM-UHFFFAOYSA-N Triclofos Chemical compound OP(O)(=O)OCC(Cl)(Cl)Cl YYQRGCZGSFRBAM-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 201000004137 episodic ataxia type 4 Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001147 triclofos Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/23—Aspartic endopeptidases (3.4.23)
- C12Y304/23019—Aspergillopepsin II (3.4.23.19)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本申请提供了酸性蛋白酶AGP及其制备方法和应用。制备酸性蛋白酶AGP的方法包括:将目的基因接入表达载体中,构建重组质粒;将所述重组质粒转化到感受态细胞之后,加入异丙基硫代半乳糖苷(IPTG)进行诱导表达;从诱导表达的蛋白中纯化得到酸性蛋白酶AGP。本申请提供的酸性蛋白水解酶AGP具有以下特点:在酸性条件(pH 2.5)和低温、少量变性剂和还原剂存在条件下依然保持比较强的活性;具有广泛的酶切位点,主要酶切位点为天门冬氨酸(Asp)、谷氨酸(Glu)、苯丙氨酸(Phe)、组氨酸(His)、赖氨酸(Lys)等,与Pepsin酶切位点具有高度互补性;AGP酶切时产生的肽段长度比Pepsin产生的肽段更短。
The application provides acid protease AGP and its preparation method and application. The method for preparing acid protease AGP comprises: inserting the target gene into an expression vector, constructing a recombinant plasmid; after the recombinant plasmid is transformed into a competent cell, adding isopropylthiogalactopyranoside (IPTG) to induce expression; The acid protease AGP was purified from the induced protein. The acidic proteolytic enzyme AGP provided by this application has the following characteristics: it still maintains relatively strong activity under acidic conditions (pH 2.5) and low temperature, and a small amount of denaturant and reducing agent; The sites are aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), histidine (His), lysine (Lys), etc., which are highly complementary to the Pepsin restriction site The peptide length produced by AGP digestion is shorter than that produced by Pepsin.
Description
技术领域technical field
本发明涉及生物质谱技术领域,更具体地,涉及酸性蛋白酶AGP及其制备方法和应用。The invention relates to the technical field of biological mass spectrometry, more specifically, to acid protease AGP and its preparation method and application.
背景技术Background technique
蛋白质是生命的基础,一切生命的表现形式,本质上都是蛋白质功能的体现。了解细胞、组织乃至整个生命体内蛋白质的结构和动态变化,会对疾病的发生、发展等过程有一个全面的认识,把握疾病诊治的关键,提高药物开发的效率。Protein is the foundation of life, and all manifestations of life are essentially the embodiment of protein functions. Understanding the structure and dynamic changes of proteins in cells, tissues, and even the entire living body will give you a comprehensive understanding of the occurrence and development of diseases, grasp the key to disease diagnosis and treatment, and improve the efficiency of drug development.
氢氘交换质谱(Hydrogen Deuterium Exchange Mass spectrometry,HDX-MS)是研究蛋白质结构的常见手段,该技术利用质谱监测蛋白骨架中酰胺氢与氘水发生交换的特性,反映蛋白质在溶液中的构象特征和动态变化。HDX-MS凭借分析快速、灵敏、样品消耗量少,适用于复杂蛋白体系分析等优势,目前已广泛应用于膜蛋白相互作用、抗体、甚至蛋白质组装和病毒研究中。由于HDX-MS主要以自下而上(Bottom up)蛋白组学方法为主,因此在MS分析之前需要采用蛋白酶酶切产生多肽。为了尽量减少氘标记蛋白表面氘与氢的回交,蛋白质样品在氘代溶液中孵育一定时间后,在pH 2.5和0℃条件下终止反应。一般来说,实验中加入猝灭溶液并调至pH 2.5,同时控制温度为0℃,从而将HDX回交速率控制到最低。但根据不同蛋白样品的性质,猝灭溶液中也会加入不同浓度的变性剂(尿素或盐酸胍)和还原剂(TCEP)帮助蛋白质变性还原,从而提高酶切效果以及序列覆盖率。为了防止在后续的分析中发生回交,猝灭之后的所有步骤都应在pH 2.5和低温下尽快完成,并利用酸性蛋白酶如胃蛋白酶(pepsin)将蛋白质酶切为肽段。一般来说,应用于HDX-MS中的蛋白酶必须满足以下关键标准,首先,在pH2.5和低温下保持活性;其次,具有广泛的酶切位点,以最大限度覆盖蛋白序列以及序列覆盖冗余度,从而获取高结构分辨率;此外,一定程度的兼容变性剂以及还原剂可以有效拓展蛋白酶的使用场景。然而,能在如此苛刻的条件下发挥作用蛋白酶类型非常有限。Hydrogen Deuterium Exchange Mass spectrometry (HDX-MS) is a common method for studying protein structure. This technology uses mass spectrometry to monitor the exchange characteristics of amide hydrogen and deuterium water in the protein backbone, reflecting the conformational characteristics and characteristics of proteins in solution. Dynamic changes. HDX-MS has been widely used in membrane protein interaction, antibody, and even protein assembly and virus research due to its advantages of rapid analysis, sensitivity, low sample consumption, and suitability for analysis of complex protein systems. Since HDX-MS is mainly based on the bottom-up (Bottom up) proteomics method, it is necessary to use protease digestion to generate peptides before MS analysis. In order to minimize the backcrossing of deuterium and hydrogen on the surface of the deuterium-labeled protein, the protein samples were incubated in the deuterated solution for a certain period of time, and then the reaction was terminated at pH 2.5 and 0 °C. In general, quenching solution was added to the experiment and adjusted to pH 2.5, while the temperature was controlled at 0°C to minimize the HDX backcrossing rate. However, according to the properties of different protein samples, different concentrations of denaturant (urea or guanidine hydrochloride) and reducing agent (TCEP) are added to the quenching solution to help protein denaturation and reduction, thereby improving the effect of enzyme digestion and sequence coverage. To prevent backcrossing in subsequent analyses, all steps after quenching should be done as soon as possible at pH 2.5 and at low temperature, and the protein should be cleaved into peptides using an acidic protease such as pepsin. In general, proteases used in HDX-MS must meet the following key criteria, first, maintain activity at pH 2.5 and low temperature; second, have a wide range of enzyme cleavage sites to maximize protein sequence coverage and sequence coverage redundancy. In addition, a certain degree of compatibility with denaturants and reducing agents can effectively expand the use scenarios of proteases. However, the types of proteases that can function under such harsh conditions are very limited.
Pepsin是最常用的HDX-MS酸性蛋白水解酶。在典型的HDX-MS实验条件下,pepsin最主要的酶切位点(P1位)为Met、Leu及Phe;而当His、Lys、Arg或Pro占据P1位时,则抑制pepsin酶活性。因此pepsin对于无序蛋白质或蛋白结构的无序区域(通常含有Pro及带电荷的氨基酸)不能充分酶切,从而影响对蛋白质生物学功能具有重要调节的无序蛋白或区域结构信息的获取。此外,Pepsin酶切产生的肽段平均长度在~14个氨基酸水平,肽段平均长度的降低有利于提高HDX-MS方法的结构分辨率。基于此,开发适用于HDX-MS实验的酸性蛋白水解酶是一项非常重要的课题。Pepsin is the most commonly used acid proteolytic enzyme for HDX-MS. Under typical HDX-MS experimental conditions, the main restriction sites (P1 position) of pepsin are Met, Leu and Phe; and when His, Lys, Arg or Pro occupy the P1 position, pepsin enzymatic activity is inhibited. Therefore, pepsin cannot fully digest disordered proteins or disordered regions of protein structures (usually containing Pro and charged amino acids), thus affecting the acquisition of disordered protein or region structure information that is important for regulating protein biological functions. In addition, the average length of the peptides produced by Pepsin digestion was at the level of ~14 amino acids, and the reduction of the average length of the peptides was conducive to improving the structural resolution of the HDX-MS method. Based on this, the development of acidic proteolytic enzymes suitable for HDX-MS experiments is a very important topic.
发明内容Contents of the invention
本申请提供了一种可以用于HDX-MS分析下酸性蛋白水解酶,该酸性蛋白酶为来自大孢子黑曲霉(Aspergillus niger var.macrosporus)的Aspergilloglutamic肽酶(AGP),属于天冬氨酸不敏感型酸性肽链内切酶。The application provides an acidic proteolytic enzyme that can be used for HDX-MS analysis. The acidic protease is Aspergilloglutamic peptidase (AGP) from Aspergillus niger var.macrosporus, which is insensitive to aspartic acid type acidic endopeptidase.
本申请提供了一种制备酸性蛋白酶AGP的方法,包括:将目的基因SEQ.ID.NO.1接入表达载体中,构建重组质粒;将所述重组质粒转化到感受态细胞之后,加入异丙基硫代半乳糖苷(IPTG)进行诱导表达;从诱导表达的蛋白中纯化得到酸性蛋白酶AGP。The application provides a method for preparing acid protease AGP, comprising: inserting the target gene SEQ.ID.NO.1 into an expression vector to construct a recombinant plasmid; after transforming the recombinant plasmid into competent cells, adding isopropyl Induced expression with thiogalactoside (IPTG); acid protease AGP was purified from the induced expressed protein.
在一些实施例中,所述诱导表达的条件为:重组表达宿主菌37℃振摇培养至OD600为0.6时,加入终浓度为1mM的异丙基硫代半乳糖苷,37℃振摇培养4h。In some embodiments, the conditions for inducing expression are: when the recombinant expression host bacteria are shaken and cultured at 37°C until the OD600 is 0.6, isopropylthiogalactoside with a final concentration of 1 mM is added, and shaken at 37°C for 4 hours .
在一些实施例中,纯化得到酸性蛋白酶AGP的纯化条件为:依次用咪唑含量为0mM、10mM、30mM各洗脱4次,洗去杂蛋白后,用咪唑含量为300mM的洗脱缓冲液洗脱目的蛋白。In some embodiments, the purification conditions to obtain the acid protease AGP are as follows: elution with imidazole content of 0mM, 10mM, and 30mM for 4 times respectively, after washing away impurities, and elution with an elution buffer with an imidazole content of 300mM target protein.
本申请还提供了通过上述方法得到的酸性蛋白酶AGP。The present application also provides the acid protease AGP obtained by the above method.
本申请还提供了酸性蛋白水解酶AGP在HDX-MS和蛋白质组学中的应用。The application also provides the application of acid proteolytic enzyme AGP in HDX-MS and proteomics.
本申请的酸性蛋白水解酶AGP具有以下特点:在酸性条件(pH 2.5)和低温、少量变性剂和还原剂存在条件下依然保持比较强的活性;具有广泛的酶切位点,主要酶切位点为天门冬氨酸(Asp)、谷氨酸(Glu)、苯丙氨酸(Phe)、组氨酸(His)、赖氨酸(Lys)等,与Pepsin酶切位点具有高度互补性;AGP酶切时产生的肽段长度比Pepsin产生的肽段更短等优点。The acidic proteolytic enzyme AGP of the present application has the following characteristics: it still maintains relatively strong activity under acidic conditions (pH 2.5) and low temperature, and a small amount of denaturant and reducing agent; The points are aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), histidine (His), lysine (Lys), etc., which are highly complementary to the Pepsin restriction site ; The length of the peptide produced by AGP digestion is shorter than that of Pepsin.
附图说明Description of drawings
图1示出了表达纯化后的蛋白酶AGP的SDS-PAGE和Western Blot图。Figure 1 shows the SDS-PAGE and Western Blot diagrams of the expressed and purified protease AGP.
图2示出了蛋白酶AGP在不同pH、温度、变性剂和还原剂条件下酶切标准肽段的活性。Figure 2 shows the activity of protease AGP to digest standard peptides under different conditions of pH, temperature, denaturant and reducing agent.
图3示出了酶切标准蛋白质混合物时,来自蛋白酶AGP和Pepsin的酶切肽段重叠情况。Figure 3 shows the overlap of digested peptides from proteases AGP and Pepsin when digesting a standard protein mixture.
图4示出了酶切标准蛋白质混合物时,来自蛋白酶AGP和Pepsin的酶切肽段长度箱线图。Figure 4 shows the boxplots of lengths of digested peptides from proteases AGP and Pepsin when the standard protein mixture is digested.
图5示出了酶切标准蛋白质混合物时,来自蛋白酶AGP和Pepsin的酶切肽段质量分布和箱线图。Figure 5 shows the mass distribution and boxplot of digested peptides from proteases AGP and Pepsin when the standard protein mixture is digested.
图6示出了蛋白酶AGP和Pepsin的酶切位点比例比较柱状图。Fig. 6 shows a histogram comparing the ratios of enzyme cleavage sites of protease AGP and Pepsin.
具体实施方式Detailed ways
下面的实施例可以使本领域技术人员更全面地理解本发明,但不以任何方式限制本发明。The following examples can enable those skilled in the art to understand the present invention more fully, but do not limit the present invention in any way.
本申请提供一种酸性蛋白水解酶AGP,来自大孢子黑曲霉(Aspergillus nigervar.macrosporus)。其有益效果是,该酶对带电荷的氨基酸位点的酶切具有明显偏好性,与pepsin酶切位点具有高度互补性,且产生的肽段平均长度短于pepsin,可将该酶用于HDX-MS实验用于蛋白质结构分析以及蛋白组学分析。The present application provides an acidic proteolytic enzyme AGP, which is derived from Aspergillus nigervar. macrosporus. The beneficial effect is that the enzyme has a clear preference for enzymatic cleavage of charged amino acid sites, is highly complementary to the pepsin cleavage site, and the average length of the generated peptides is shorter than that of pepsin, and the enzyme can be used for HDX-MS experiments are used for protein structure analysis as well as proteomics analysis.
本发明提供的酸性蛋白水解酶AGP来自重组表达。The acid proteolytic enzyme AGP provided by the invention comes from recombinant expression.
1、AGP的表达步骤1. The expression steps of AGP
将目的基因SEQ.ID.NO.1(SEQ.ID.NO.1的基因序列为:AtgggtcaccatcaccatcaccatatgtcggactcagaagtcaatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatggatcttcagagatcttcttcaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggtaaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatggaggataacgatattattgaggctcacagagaacagattggtggccaaGGATCCGCGCCGCTGACCGAAAAACGCCGCGCGCGCAAAGAAGCGCGCGCGGCGGGCAAACGCCATAGCAACCCGCCGTATATTCCGGGCAGCGATAAAGAAATTCTGAAACTGAACGGCACCAGCAACGAAGATTATAGCAGCAACTGGGCGGGCGCGGTGCTGATTGGCGATGGCTATACCAAAGTGACCGGCGAATTTACCGTGCCGAGCGTGAGCGCGGGCAGCAGCAGCAGCAGCGGCTATGGCGGCGGCTATGGCTATTATAAAAACAAACGCCAGAGCGAAGAATATTGCGCGAGCGCGTGGGTGGGCATTGATGGCGATACCTGCGAAACCGCGATTCTGCAGACCGGCGTGGATTTTTGCTATGAAGATGGCCAGACCAGCTATGATGCGTGGTATGAATGGTATCCGGATTATGCGTATGATTTTAACGATATTACCATTAGCGAAGGCGATACCATTAAAGTGACCGTGGAAGCGACCAGCAAAAGCAGCGGCAGCGCGACCGTGGAAAACCTGACCACCGGCCAGAGCGTGACCCATACCTTTAGCGGCAACGTGGAAGGCGATCTGTGCGAAACCAACGCGGAATGGATTGTGGAAGATTTTGAAAGCGGCGATAGCCTGGTGGCGTTTGCGGATTTTGGCAGCGTGACCTTTACCAACGCGGAAGCGACCAGCGATGGCAGCACCGTGGGCCCGAGCGATGCGACCGTGATGGATATTGAACAGGATGGCACCGTGCTGACCGAAACCAGCGTGAGCGGCGATAGCGTGACCGTGACCTATGTGTAACTCGAG)接入PATX-SUMO表达载体中(克隆策略:BamHI/XhoI),构建重组质粒。用该质粒转化BL21感受态细胞后,加入异丙基硫代半乳糖苷(IPTG)进行诱导表达,经过一系列条件探索,最终确定表达条件为:重组表达宿主菌37℃振摇培养至OD600约为0.6时,加入终浓度为1mM的IPTG,37℃振摇培养4h。使用Nickel磁珠提取纯化蛋白酶AGP,确定纯化条件为依次用咪唑含量为0mM、10mM、30mM各洗脱4次,洗去杂蛋白后,用咪唑含量为300mM的洗脱缓冲液洗脱目的蛋白。收获的蛋白进行SDS-PAGE和Western Blot鉴定。The gene sequence of the target gene SEQ.ID.NO.1 (SEQ.ID.NO.1 is: Atgggtcaccatcaccatcaccatgtcggactcagaagtcaatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatggatcttcagagatcttcttcaagatcaaaaaagaccactcctttaagaagg ctgatggaagcgttcgctaaaagacagggtaaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatggaggataacgatattattgaggctcacagagaacagattggtggccaaGGATCCGCGCCGCTGACCGAAAAACGCCGCGCGCGCAAAGAAGCGCGCGGCGGGCAAACG CCATAGCAACCCGCCGTATATTCCGGGCAGCGATAAAGAAATTCTGAAACTGAACGGCACCAGCAACGAAGATTATAGCAGCAACTGGGCGGGCGCGGTGCTGATTGGCGATGGCTATACCAAAGTGACCGGCGAATTTACCGTGCCGAGCGTGAGCGCGGCAGCAGCAGCAGCAGCGGCTATGGCGGCGGCTATGGCTATTATAAAACAAAC GCCAGAGCGAAGAATATTGCGCGAGCGCGTGGGTGGGCATTGATGGCGATACCTGCGAAACCGCGATTCTGCAGACCGGCGTGGATTTTTGCTATGAAGATGGCCAGACCAGCTATGATGCGTGGTATGAATGGTATCCGGATTATGCGTATGATTTTAACGATATTACCATTAGCGAAGGCGATACCATTAAAGTGACCGTGGAAGCGACCAGCAAAAGCAGC GGCAGCGCGACCGTGGAAAACCTGACCACCGGCCAGAGCGTGACCCATACCTTTAGCGGCAACGTGGAAGGCGATCTGTGCGAAACCAACGCGGAATGGATTGTGGAAGATTTTGAAAGCGGCGATAGCCTGGTGGCGTTTGCGGATTTTGGCAGCGTGACCTTTACCAACGCGGAAGCGACCAGCGATGGCAGCACCGTGGGCCCGAGCGATGCGA CCGTGATGGATATTGAACAGGATGGCACCGTGCTGACCGAAACCAGCGTGAGCGGCGATAGCGTGACCGTGACCTATGTGTAACTCGAG) was inserted into the PATX-SUMO expression vector (cloning strategy: BamHI/XhoI) to construct a recombinant plasmid. After using this plasmid to transform BL21 competent cells, add isopropylthiogalactopyranoside (IPTG) to induce expression. After a series of conditional explorations, the expression conditions were finally determined: the recombinant expression host bacteria were shaken and cultured at 37°C to an OD600 of about When it was 0.6, IPTG with a final concentration of 1 mM was added, and cultured with shaking at 37°C for 4h. Nickel magnetic beads were used to extract and purify the protease AGP, and the purification conditions were determined to be eluted four times with imidazole content of 0mM, 10mM, and 30mM respectively. The harvested proteins were identified by SDS-PAGE and Western Blot.
(1)SDS-PAGE及Western Blot鉴定方法(1) SDS-PAGE and Western Blot identification method
取蛋白酶样品,按1:4体积比例,加入5×SDS-PAGE loading buffer混匀后,95℃加热5min使蛋白变性。准备SDS-PAGE胶进行上样。样品进胶前电压控制在100~200V,当样品中的溴酚蓝指示剂到达分离胶之后,电压升到200V,电泳过程保持电压稳定。电泳结束后取出凝胶,加入考马斯亮蓝染液慢摇1h。倒去染液,蒸馏水洗净后加适量脱色液,快摇洗脱至条带清晰。然后进行Western Blot鉴定。电泳将蛋白转移到聚偏氟乙烯膜(Polyvinylidene fluoride,PVDF)上。冰上电转,230mA恒流电转80min,电压保持在90V以上。电转结束后,室温下用5%牛奶浸泡PVDF转印膜,慢摇1h封闭孔隙。再用1×TBST溶液快摇洗膜4次,每次5min。将膜置于His-tag抗体稀释液中,4℃旋转孵育过夜。孵育结束后,取出PVDF膜,用1×TBST溶液快摇洗膜4次,每次5min。将膜置于鼠二抗稀释液中,常温下旋转孵育1h,再用1×TBST溶液快摇洗膜4次,每次5min,即可显影。Take a protease sample, add 5×SDS-PAGE loading buffer at a volume ratio of 1:4, mix well, and heat at 95°C for 5 minutes to denature the protein. Prepare SDS-PAGE gel for loading. Before the sample enters the gel, the voltage is controlled at 100-200V. When the bromophenol blue indicator in the sample reaches the separation gel, the voltage is raised to 200V, and the voltage is kept stable during the electrophoresis process. After electrophoresis, the gel was taken out, and Coomassie brilliant blue staining solution was added and shaken slowly for 1 h. Pour off the dye solution, wash with distilled water, add an appropriate amount of decolorization solution, and shake quickly to elute until the bands are clear. Then carry out Western Blot identification. The protein was transferred to polyvinylidene fluoride (PVDF) membrane by electrophoresis. Electroporation on ice, 230mA constant current electroporation for 80min, voltage kept above 90V. After electrotransfer, soak the PVDF transfer membrane with 5% milk at room temperature, and shake slowly for 1 hour to seal the pores. Then wash the membrane with 1 × TBST solution for 4 times, 5 min each time. Place the membrane in His-tag antibody diluent and incubate overnight at 4°C with rotation. After the incubation, the PVDF membrane was taken out, and the membrane was quickly shaken and washed 4 times with 1×TBST solution, 5 min each time. Place the membrane in the diluent of the mouse secondary antibody, incubate with rotation at room temperature for 1 h, then wash the membrane with 1× TBST solution for 4 times, each time for 5 min, and develop.
(2)结果(2) Results
考马斯亮蓝染色结果如图1中的A所示,Western Blot结果如图1中的B所示,在分子量50kDa处均可观察到蛋白酶AGP的条带。The results of Coomassie brilliant blue staining are shown in A in Figure 1, and the results of Western Blot are shown in B in Figure 1. The band of protease AGP can be observed at a molecular weight of 50 kDa.
2、AGP酶切条件的考察2. Investigation of AGP digestion conditions
(1)酶切方法(1) enzyme digestion method
AGP与标准肽段Substance P(RPKPQQFFGLM)以1:10(W/W)的比例分别在pH 1、pH2.5、pH 5和pH 7的溶液中37℃孵育15分钟。反应产物通过LC-MS方法进行测定。AGP and the standard peptide Substance P (RPKPQQFFGLM) were incubated at a ratio of 1:10 (W/W) at pH 1, pH 2.5, pH 5, and pH 7 at 37°C for 15 minutes. The reaction products were determined by LC-MS method.
(2)结果(2) Results
结果如图2中的a所示,在pH 1-2.5的酸性条件下,检测到的物质主要以SubstanceP的水解片段RPKPQQFF为主,说明AGP在酸性条件下有活性;而当pH≥4时,检测到的物质主要为Substance P本身为主,此时AGP的活性显著下降。除了在室温条件下,在0℃时也观察到同样的趋势。为了激活AGP活性并在低温下获得更好的酶切效率,在加入底物之前,将AGP在室温下平衡10min,与0℃相比,在pH=2.5时活性约提高了46%。HDX-MS实验中的猝灭步骤通常涉及变性剂和还原剂的使用,因此,在酶活性测试基础上,进一步考察了HDX MS实验条件下,即0℃和酸性pH值(2.5)条件下,增加尿素或变性剂(TCEP,磷酸三氯乙酯)浓度时的AGP活性水平。如图2中的b所示,当尿素(Urea)浓度增加到1.5M时,AGP仍保留50%左右的活性。如图2中的c所示,当TCEP浓度增加到200mM,AGP活性保留40%左右。The results are shown in a in Figure 2. Under acidic conditions of pH 1-2.5, the detected substances are mainly the hydrolyzed fragment RPKPQQFF of SubstanceP, indicating that AGP is active under acidic conditions; and when pH ≥ 4, The detected substances are mainly Substance P itself, and the activity of AGP drops significantly at this time. The same trend was also observed at 0 °C except at room temperature. In order to activate AGP activity and obtain better digestion efficiency at low temperature, AGP was equilibrated at room temperature for 10 min before adding the substrate. Compared with 0°C, the activity increased by about 46% at pH=2.5. The quenching step in HDX-MS experiments usually involves the use of denaturants and reducing agents. Therefore, based on the enzyme activity test, the HDX MS experiment conditions, namely 0 °C and acidic pH (2.5) conditions, were further investigated. AGP activity levels at increasing concentrations of urea or denaturing agents (TCEP, trichloroethyl phosphate). As shown in b in Figure 2, when the concentration of urea (Urea) increased to 1.5M, AGP still retained about 50% of its activity. As shown in c in Fig. 2, when the concentration of TCEP was increased to 200 mM, the AGP activity remained about 40%.
3、蛋白水解酶AGP和Pepsin酶切比较3. Comparison of proteolytic enzymes AGP and Pepsin digestion
(1)酶切方法(1) enzyme digestion method
取5ug标准蛋白混合物(表1),加入终浓度为8M的尿素和10mM的二硫苏糖醇(DTT),37℃孵育2h使蛋白质变性并打开二硫键。反应完毕后向反应体系加入终浓度为20mM的吲哚-3-乙酸(IAA),室温避光条件下反应40min封闭二硫键。反应完毕后加入7倍体积的缓冲液稀释尿素浓度至1M,蛋白水解酶AGP所用缓冲液为0.2M甘氨酸-盐酸缓冲液(pH 2.2),pepsin所用缓冲液为10mM HCl(pH 2.0),将底物蛋白质溶液的pH调至2-2.5,按1:20(w/w)的酶与蛋白质比例加入AGP或pepsin,37℃反应6h,反应结束后加热终止反应。样品经除盐后进LC-MS进行分析,每个样品重复三次进样。表1示出了标准蛋白混合物信息。Take 5ug of the standard protein mixture (Table 1), add urea and 10mM dithiothreitol (DTT) at a final concentration of 8M, and incubate at 37°C for 2h to denature the protein and open the disulfide bond. After the reaction was completed, indole-3-acetic acid (IAA) with a final concentration of 20 mM was added to the reaction system, and the disulfide bond was blocked by reacting for 40 min at room temperature and protected from light. After completion of the reaction, add 7 times the volume of buffer to dilute the urea concentration to 1M. The buffer used by proteolytic enzyme AGP is 0.2M glycine-hydrochloric acid buffer (pH 2.2), and the buffer used by pepsin is 10mM HCl (pH 2.0). Adjust the pH of the protein solution to 2-2.5, add AGP or pepsin according to the ratio of enzyme to protein of 1:20 (w/w), react at 37°C for 6 hours, and heat to terminate the reaction after the reaction is completed. The samples were analyzed by LC-MS after desalting, and each sample was injected three times. Table 1 shows standard protein mix information.
表1Table 1
(2)结果(2) Results
结果如图3所示,三次重复进样中,AGP酶切共产生1264条3针重复出现的肽段,pepsin共产生1306条3针重复出现的肽段,通过对比发现其中仅有149条肽段重合,说明AGP酶切位点与pepsin具有高度互补性。另外,AGP酶切产生的肽段更多分布在m/z 2000以内,其平均肽段长度中位数为12(m/z 1383.20);而pepsin酶切产生的肽段更多分布在m/z1000-3000,平均肽段长度中位数为14(m/z 1603.82)(图4-图5)。因此,AGP可以产生比pepsin酶切更短的肽段,对于基于HDX-MS的蛋白质结构分析而言,可以获得更高的结构分辨率。The results are shown in Figure 3. In the three repeated injections, AGP digestion produced a total of 1264 peptides with 3 repeats, and pepsin produced 1306 peptides with 3 repeats. Only 149 peptides were found by comparison. The segments coincide, indicating that the AGP restriction site is highly complementary to pepsin. In addition, the peptides produced by AGP digestion are more distributed within m/z 2000, and the median length of the average peptide is 12 (m/z 1383.20); while the peptides produced by pepsin digestion are more distributed in m/z z1000-3000, the median length of the average peptide segment is 14 (m/z 1603.82) (Figure 4-Figure 5). Therefore, AGP can produce shorter peptides than pepsin, which can achieve higher structural resolution for HDX-MS-based protein structure analysis.
如图6所示,AGP具有广泛的酶切位点,并优先酶切P1位点上带电荷的氨基酸类型,包括His(11.74%)、Lys(9.41%)、Glu(14.14%)、Asp(11.66%)和Phe(10.05%);而pepsin优先酶切Leu(25.66%)、Phe(12.83%)和Glu(12.99%),且pepsin在His位点几乎不发生酶切(0.23%)。除此之外,AGP在Asn(6.51%)、Gln(5.31%)、Arg(4.10%)位点的酶切比例显著高于pepsin(对应1.32%、1.63%、2.02、0.70%)。由此可见,AGP与Pepsin的酶切位点具有互补性,并且可以用于无序蛋白质或蛋白质的无序区域的结构信息获取。As shown in Figure 6, AGP has a wide range of enzyme cutting sites, and preferentially cuts the charged amino acid types on the P1 site, including His (11.74%), Lys (9.41%), Glu (14.14%), Asp ( 11.66%) and Phe (10.05%); while pepsin preferentially cuts Leu (25.66%), Phe (12.83%) and Glu (12.99%), and pepsin hardly cuts at His site (0.23%). In addition, the restriction ratios of AGP at Asn (6.51%), Gln (5.31%), and Arg (4.10%) sites were significantly higher than those of pepsin (corresponding to 1.32%, 1.63%, 2.02, and 0.70%). It can be seen that the cleavage sites of AGP and Pepsin are complementary, and can be used to obtain structural information of disordered proteins or disordered regions of proteins.
因此,本申请的蛋白水解酶AGP在pH2.5、低温、有适量变性剂和还原剂存在条件下仍保持较高的活性,具有广泛的酶切位点,主要酶切位点为His、Lys、Glu等,与pepsin酶切位点具有高度互补性,且产生的肽段长度比pepsin酶切的肽段更短等优点,可以用于HDX-MS实验条件下的蛋白酶切以及常规蛋白质组学中的酶切反应。Therefore, the proteolytic enzyme AGP of the present application still maintains high activity under the conditions of pH 2.5, low temperature, and the presence of an appropriate amount of denaturant and reducing agent, and has a wide range of enzyme cleavage sites, the main enzyme cleavage sites are His and Lys , Glu, etc., are highly complementary to the pepsin cleavage site, and the resulting peptides are shorter than pepsin cleavage peptides, which can be used for protease cleavage and routine proteomics under HDX-MS experimental conditions enzyme cleavage reaction.
本领域技术人员应理解,以上实施例仅是示例性实施例,在不背离本发明的精神和范围的情况下,可以进行多种变化、替换以及改变。Those skilled in the art should understand that the above embodiments are only exemplary embodiments, and various changes, substitutions and changes can be made without departing from the spirit and scope of the present invention.
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310040621.1A CN116144687B (en) | 2023-01-13 | 2023-01-13 | Acid protease AGP and its preparation method and application |
PCT/CN2024/071262 WO2024149219A1 (en) | 2023-01-13 | 2024-01-09 | Acid protease agp, preparation method therefor, and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310040621.1A CN116144687B (en) | 2023-01-13 | 2023-01-13 | Acid protease AGP and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116144687A CN116144687A (en) | 2023-05-23 |
CN116144687B true CN116144687B (en) | 2023-09-01 |
Family
ID=86355636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310040621.1A Active CN116144687B (en) | 2023-01-13 | 2023-01-13 | Acid protease AGP and its preparation method and application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116144687B (en) |
WO (1) | WO2024149219A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116144687B (en) * | 2023-01-13 | 2023-09-01 | 中山大学 | Acid protease AGP and its preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101914555A (en) * | 2001-02-23 | 2010-12-15 | Dsmip资产有限公司 | Novel genes encoding novel proteolytic enzymes |
CN104582503A (en) * | 2012-08-14 | 2015-04-29 | 帝斯曼知识产权资产管理有限公司 | Protein hydrolysate |
CN104640996A (en) * | 2012-09-18 | 2015-05-20 | 帝斯曼知识产权资产管理有限公司 | Process for producing gelatin employing aspergillopepsin II |
CN112458106A (en) * | 2020-12-04 | 2021-03-09 | 中国海洋大学 | Preparation method of multi-copy golden pomfret delicious peptide, expression vector and recombinant bacteria |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018067398A1 (en) * | 2016-10-03 | 2018-04-12 | Waters Technologies Corporation | Labeled glycan amino acid complexes useful in lc-ms analysis and methods of making the same |
CN116144687B (en) * | 2023-01-13 | 2023-09-01 | 中山大学 | Acid protease AGP and its preparation method and application |
-
2023
- 2023-01-13 CN CN202310040621.1A patent/CN116144687B/en active Active
-
2024
- 2024-01-09 WO PCT/CN2024/071262 patent/WO2024149219A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101914555A (en) * | 2001-02-23 | 2010-12-15 | Dsmip资产有限公司 | Novel genes encoding novel proteolytic enzymes |
CN104582503A (en) * | 2012-08-14 | 2015-04-29 | 帝斯曼知识产权资产管理有限公司 | Protein hydrolysate |
CN104640996A (en) * | 2012-09-18 | 2015-05-20 | 帝斯曼知识产权资产管理有限公司 | Process for producing gelatin employing aspergillopepsin II |
CN112458106A (en) * | 2020-12-04 | 2021-03-09 | 中国海洋大学 | Preparation method of multi-copy golden pomfret delicious peptide, expression vector and recombinant bacteria |
Non-Patent Citations (1)
Title |
---|
Sasaki, H等.The crystal structure of an intermediate dimer of aspergilloglutamic peptidase that mimics the enzyme-activation product complex produced upon autoproteolysis.《JOURNAL OF BIOCHEMISTRY》.2012,第152卷(第1期),第45-52页. * |
Also Published As
Publication number | Publication date |
---|---|
CN116144687A (en) | 2023-05-23 |
WO2024149219A1 (en) | 2024-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eckhard et al. | Proteomic protease specificity profiling of clostridial collagenases reveals their intrinsic nature as dedicated degraders of collagen | |
EP2756077B1 (en) | Endoglycosidase from streptococcus pyogenes and methods using it | |
US20190390203A1 (en) | Reduction of lipase activity in product formulations | |
Noiva | Enzymatic catalysis of disulfide formation | |
JP2018502848A (en) | Microbial transglutaminase, its substrate, and method of use | |
Barrett | Human cathepsin D | |
CN116144687B (en) | Acid protease AGP and its preparation method and application | |
CN103756983B (en) | Preparation method of uricase of natural mammals | |
CN107400666B (en) | A kind of aminopeptidase and its coding gene and application | |
US20210348148A1 (en) | Method of purifying active soluble matrix metalloproteinases | |
CN110746499A (en) | Serum amyloid protein A mutant and application and preparation method thereof | |
CN109439643B (en) | Novel lysine specific endonuclease and preparation method thereof | |
Fujimoto et al. | Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin | |
Hofmann | [49] Penicillocarboxypeptidases S-1 and S-2 | |
US6461834B1 (en) | Clostripain catalyzed amidation of peptides | |
WO2019062709A1 (en) | Recombinant bovine serum albumin mature peptide, preparation method therefor, and application thereof | |
Kiser et al. | Streptomyces erythraeus trypsin for proteomics applications | |
CA2777650A1 (en) | Electrophoretic analysis method | |
Ottesen et al. | Stepwise degradation of the peptides liberated in the transformation of ovalbumin to plakalbumin | |
CN116854808A (en) | A kind of human type III collagen and preparation method thereof | |
CN110437331B (en) | Method for improving inclusion body protein renaturation of smooth turtle shell serine protease inhibitor | |
IE62228B1 (en) | A method for the selective cleavage of fusion proteins | |
Singh et al. | Purification and characterization of a pineapple crown leaf thiol protease | |
RU2740319C1 (en) | Method for increasing activity of triticaine-alpha | |
WO2020113552A1 (en) | Recombinant acetylated lysine arginine n-terminal protease, preparation method therefor, and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |